Bausch + Lomb to Showcase Company Evolution and Growth Plans During Investor Day
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy BLCO?
Source: Newsfilter
Company Transformation: Bausch + Lomb has undergone a significant transformation, focusing on simplification, accountability, and innovation, while integrating AI and new technologies to enhance its operations and culture.
Financial Growth Targets: The company aims for a 5-7% constant currency revenue CAGR through 2028, with plans for margin expansion and double-digit adjusted annual earnings per share growth from 2026 to 2028.
Innovative Product Pipeline: Bausch + Lomb's investor day highlighted a robust product pipeline with projected peak sales of around $7 billion, featuring innovations across consumer, pharmaceutical, surgical, and contact lens segments.
Commitment to Eye Health: The company emphasizes its mission to improve eye health through innovative solutions, aiming to address both common and complex eye diseases with a focus on patient care and sustainable growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLCO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLCO
Wall Street analysts forecast BLCO stock price to rise
10 Analyst Rating
4 Buy
5 Hold
1 Sell
Moderate Buy
Current: 16.730
Low
13.00
Averages
18.11
High
21.00
Current: 16.730
Low
13.00
Averages
18.11
High
21.00
About BLCO
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bausch + Lomb Launches Fifth Annual Glaucoma Fundraising Challenge with $20,000 Match
- Fundraising Challenge: Bausch + Lomb is launching its fifth annual fundraising challenge in partnership with the Glaucoma Research Foundation during Glaucoma Awareness Month, pledging to match every dollar raised up to $20,000 in January to support critical glaucoma research aimed at enhancing public awareness of this leading cause of blindness.
- Social Media Campaign: The company will also sponsor The Glaucoma Foundation's social media campaign, which highlights a glaucoma patient or advocate's story each day in January, thereby raising awareness of the disease's impact and emphasizing the importance of early detection to help more individuals focus on eye health.
- Disease Impact: Currently, approximately four million people in the United States are affected by glaucoma, and this number is expected to grow as the population ages, making enhanced education and research vital for improving the quality of life for those affected.
- Strategic Collaboration: The partnership between Bausch + Lomb, the Glaucoma Research Foundation, and The Glaucoma Foundation not only advances glaucoma research but also encourages public awareness and proactive eye health measures, reflecting the company's commitment and responsibility in the eye health sector.
See More
Bausch + Lomb Completes $2.8 Billion Credit Agreement Refinancing
- Credit Agreement Refinancing: Bausch + Lomb has completed a $2.8 billion credit agreement refinancing, utilizing the Fourth Amendment to refinance maturing loans, thereby alleviating future financial pressure.
- Loan Terms Optimization: The new loans feature an amortization rate of 1.00% per annum, with the first installment due on June 30, 2026, which is expected to improve the company's cash flow management compared to previous terms.
- Interest Rate Reduction: The applicable margin for the replacement loans is reduced by 0.50% and 0.25% from prior loans, which will help lower financing costs and enhance financial flexibility for the company.
- Maturity Extension: The new loans will mature on January 15, 2031, extending the maturity of existing loans and allowing the company to better plan its financial strategy over the coming years.
See More
Bausch + Lomb to Present at 2026 J.P. Morgan Healthcare Conference
- Executive Participation: Bausch + Lomb's Chairman and CEO Brent Saunders will speak at the J.P. Morgan Healthcare Conference on January 12, 2026, showcasing the company's latest advancements in eye health, which is expected to attract investor interest.
- Financial Leadership Involvement: CFO Sam Eldessouky will also participate in the conference, providing updates on the company's financial status, aimed at bolstering investor confidence in the company's future growth.
- R&D Leadership Presentation: Chief Medical Officer and Head of R&D Yehia Hashad, MD, will discuss the company's innovative products, emphasizing Bausch + Lomb's commitment to research and development in eye health, potentially enhancing market recognition of its offerings.
- Live Webcast: The event will be available via live webcast on Bausch + Lomb's Investor Relations page, ensuring that investors unable to attend in person can access key information, further enhancing the company's transparency and investor relations.
See More
Bausch + Lomb Appoints Two New Directors to Accelerate Strategy
- New Board Members: Bausch + Lomb announced the appointment of Dr. Eduardo C. Alfonso and Steven H. Collis to its board effective January 1, 2026, expanding the board to 10 members, aimed at enhancing strategic execution through diversified leadership.
- Industry Expert Addition: Dr. Alfonso is a globally recognized ophthalmologist with a strong background in corneal diseases from Bascom Palmer Eye Institute, whose expertise will provide critical guidance for the company's innovations in eye health.
- Financial Growth Driver: Collis led Cencora to triple its annual revenue and significantly expanded its global presence through strategic acquisitions, and his extensive financial management experience will support Bausch + Lomb's sustainable growth.
- Future Strategic Direction: The addition of these two directors not only enhances the board's expertise but also propels Bausch + Lomb's innovation and development in the eye health market, helping the company seize significant future opportunities.
See More
Bausch + Lomb Allocates $2.8B for Loan Refinancing
- Financing Scale: Bausch + Lomb announced the allocation of $2.8 billion in new loans aimed at refinancing maturing loans, reflecting proactive financial management by the company.
- Interest Rate Reduction: The new loans feature a 0.50% and 0.25% reduction in applicable margins, which will lower financial costs and enhance profitability.
- Maturity Extension: The new loans will mature on January 15, 2031, extending the maturity of previously due loans from 2028, thereby improving cash flow management for the company.
- Transaction Timeline: These transactions are expected to close in the first quarter of 2026; while uncertainties exist, successful completion would bolster the company's financial stability.
See More
Bausch + Lomb Restructures Existing Term B Loans
Company Overview: Bausch + Lomb is a global eye health company that has made recent announcements regarding its financial allocations.
Market Activity: The company made its announcement following trade activities on Friday, indicating potential movements in its stock performance.
See More
Bausch + Lomb Launches Fifth Annual Glaucoma Fundraising Challenge with $20,000 Match
- Fundraising Challenge: Bausch + Lomb is launching its fifth annual fundraising challenge in partnership with the Glaucoma Research Foundation during Glaucoma Awareness Month, pledging to match every dollar raised up to $20,000 in January to support critical glaucoma research aimed at enhancing public awareness of this leading cause of blindness.
- Social Media Campaign: The company will also sponsor The Glaucoma Foundation's social media campaign, which highlights a glaucoma patient or advocate's story each day in January, thereby raising awareness of the disease's impact and emphasizing the importance of early detection to help more individuals focus on eye health.
- Disease Impact: Currently, approximately four million people in the United States are affected by glaucoma, and this number is expected to grow as the population ages, making enhanced education and research vital for improving the quality of life for those affected.
- Strategic Collaboration: The partnership between Bausch + Lomb, the Glaucoma Research Foundation, and The Glaucoma Foundation not only advances glaucoma research but also encourages public awareness and proactive eye health measures, reflecting the company's commitment and responsibility in the eye health sector.
See More
Bausch + Lomb Completes $2.8 Billion Credit Agreement Refinancing
- Credit Agreement Refinancing: Bausch + Lomb has completed a $2.8 billion credit agreement refinancing, utilizing the Fourth Amendment to refinance maturing loans, thereby alleviating future financial pressure.
- Loan Terms Optimization: The new loans feature an amortization rate of 1.00% per annum, with the first installment due on June 30, 2026, which is expected to improve the company's cash flow management compared to previous terms.
- Interest Rate Reduction: The applicable margin for the replacement loans is reduced by 0.50% and 0.25% from prior loans, which will help lower financing costs and enhance financial flexibility for the company.
- Maturity Extension: The new loans will mature on January 15, 2031, extending the maturity of existing loans and allowing the company to better plan its financial strategy over the coming years.
See More
Bausch + Lomb to Present at 2026 J.P. Morgan Healthcare Conference
- Executive Participation: Bausch + Lomb's Chairman and CEO Brent Saunders will speak at the J.P. Morgan Healthcare Conference on January 12, 2026, showcasing the company's latest advancements in eye health, which is expected to attract investor interest.
- Financial Leadership Involvement: CFO Sam Eldessouky will also participate in the conference, providing updates on the company's financial status, aimed at bolstering investor confidence in the company's future growth.
- R&D Leadership Presentation: Chief Medical Officer and Head of R&D Yehia Hashad, MD, will discuss the company's innovative products, emphasizing Bausch + Lomb's commitment to research and development in eye health, potentially enhancing market recognition of its offerings.
- Live Webcast: The event will be available via live webcast on Bausch + Lomb's Investor Relations page, ensuring that investors unable to attend in person can access key information, further enhancing the company's transparency and investor relations.
See More
Bausch + Lomb Appoints Two New Directors to Accelerate Strategy
- New Board Members: Bausch + Lomb announced the appointment of Dr. Eduardo C. Alfonso and Steven H. Collis to its board effective January 1, 2026, expanding the board to 10 members, aimed at enhancing strategic execution through diversified leadership.
- Industry Expert Addition: Dr. Alfonso is a globally recognized ophthalmologist with a strong background in corneal diseases from Bascom Palmer Eye Institute, whose expertise will provide critical guidance for the company's innovations in eye health.
- Financial Growth Driver: Collis led Cencora to triple its annual revenue and significantly expanded its global presence through strategic acquisitions, and his extensive financial management experience will support Bausch + Lomb's sustainable growth.
- Future Strategic Direction: The addition of these two directors not only enhances the board's expertise but also propels Bausch + Lomb's innovation and development in the eye health market, helping the company seize significant future opportunities.
See More
Bausch + Lomb Allocates $2.8B for Loan Refinancing
- Financing Scale: Bausch + Lomb announced the allocation of $2.8 billion in new loans aimed at refinancing maturing loans, reflecting proactive financial management by the company.
- Interest Rate Reduction: The new loans feature a 0.50% and 0.25% reduction in applicable margins, which will lower financial costs and enhance profitability.
- Maturity Extension: The new loans will mature on January 15, 2031, extending the maturity of previously due loans from 2028, thereby improving cash flow management for the company.
- Transaction Timeline: These transactions are expected to close in the first quarter of 2026; while uncertainties exist, successful completion would bolster the company's financial stability.
See More
Bausch + Lomb Restructures Existing Term B Loans
Company Overview: Bausch + Lomb is a global eye health company that has made recent announcements regarding its financial allocations.
Market Activity: The company made its announcement following trade activities on Friday, indicating potential movements in its stock performance.
See More
